Tag Archives: healthcare

CVC successfully concludes public delisting offer for CompuGroup Medical

CVC Capital Partners
  • CVC has secured total stake of 27.78% of the share capital and voting rights in CompuGroup Medical; founding family Gotthardt retains majority stake of 50.12%
  • CVC as second anchor shareholder will support CompuGroup Medical to focus on implementation of its long-term innovation and growth strategy
  • Delisting from the regulated market of the Frankfurt Stock Exchange (Prime Standard) effective as of expiry of June 24, 2025
  • Following completion of the delisting, CVC will join CompuGroup Medical’s expanded Administrative Board with three seats; founding family Gotthardt will remain in control

Caesar BidCo GmbH, a holding company owned by investment funds advised and managed by CVC Capital Partners (“CVC”), has announced the final results of the public delisting offer to all shareholders of CompuGroup Medical SE & Co. KGaA (“CompuGroup Medical” or “CGM”). At the end of the acceptance period on June 24, 2025, the delisting offer was accepted for approximately 3.39% of all shares in CompuGroup Medical. In total, CVC has secured a stake of approximately 27.78% of the share capital in CGM via the bidder as of today. The shareholders around the founding family Gotthardt retain their majority stake and continue to hold approximately 50.12% of all shares in CompuGroup Medical. There will be no additional acceptance period, and the delisting offer is not subject to any closing conditions.

The delisting of CompuGroup Medical from the Frankfurt Stock Exchange has become effective as of expiry of June 24, 2025. Following the completion of the delisting from the regulated market of the Frankfurt Stock Exchange (XETRA) and from the segment of the
regulated market with additional post-admission obligations (Prime Standard) of the Frankfurt Stock Exchange, the management of CompuGroup Medical has promptly taken action to terminate the inclusion of CGM shares in the open market (Freiverkehr) of the stock exchanges in Berlin (Second Regulated Market), Düsseldorf, Hamburg, Hanover, Munich, Stuttgart, as well as via Tradegate Exchange.

Effective July onwards, the Administrative Board of CompuGroup Medical will expand from five to six members, reflecting the terms of the Investment Agreement with CVC. As part of this agreement, CVC will secure representation on the Administrative Board with three seats. The founding family Gotthardt will retain control of the Administrative Board, represented by three representatives, including Frank Gotthardt as Chairman, Prof. (apl.) Dr. Daniel Gotthardt and Dr. Klaus Esser. Joining the Administrative Board as CVC representatives are Dr. Daniel Pindur, Can Toygar and Christoph Röttele. Together, the Gotthardt family and CVC will bring in their joint expertise to drive the execution of CGM’s long-term growth and innovation strategy.

Frank Gotthardt, Chairman of the Administrative Board of CompuGroup Medical, said: I would like to sincerely thank Stefanie Peters and Prof. (apl.) Dr. med. Karl Heinz Weiss for their support of CGM during their tenure as members of the Administrative Board. I am looking forward to driving innovation and growth together with CVC in the years to come. For no one should suffer or die because at some time medical information was missing.”

Dr. Daniel Pindur, Managing Partner at CVC, said: “With our partnership with CGM and the successful delisting, we are entering the next chapter of CompuGroup Medical’s success story. Together, we will be able to invest in a long-term and strategic manner to expand CGM’s leading market position.” Can Toygar, Partner at CVC, added: “In collaboration with the Gotthardt family, we will focus on investing in the future of the company, driving product development and delivering outstanding solutions for CGM’s customers.”

CGM and CVC first announced their strategic partnership and the planned subsequent delisting of CGM on December 9, 2024. In this context, CVC published a voluntary public tender offer to all CGM shareholders. On April 17, 2025, the bidder announced receiving the final regulatory approval for its voluntary public tender offer. The strategic partnership between CVC and CGM officially came into effect upon completion of the offer on May 2, 2025. Subsequently, CompuGroup Medical and CVC announced the signing of an agreement to delist CGM from the stock exchange on May 8, 2025. For this purpose, CVC launched a public delisting offer to all shareholder of CompuGroup Medical on May 23, 2025.

The completion of the public delisting offer will take place within the next eight banking days, i.e. on July 9, 2025 the latest. Shareholders of CompuGroup Medical who tendered their shares in the public delisting offer will be paid the offer price of EUR 22.00 per share. Further information on the settlement and transfer of the tendered shares is available on the following website: https://www.practice-public-offer.com/en.

Categories: News

Tags:

Vision Innovation Partners Acquires Eye Care of Delaware

Gryphon Investors
Annapolis, Maryland – 

Strengthens Eye Care Platform’s Services in Mid-Atlantic Region

Vision Innovation Partners (“VIP”), a leading Mid-Atlantic eye care platform with 68 locations, today announced that it has acquired Eye Care of Delaware, a provider of eye surgery and related treatments in the Mid-Atlantic area. This acquisition marks VIP’s 26th add-on since its founding in 2017 and strengthens its growing network of ophthalmology practices.

Founded in 1997, Eye Care of Delaware offers eye surgery and related treatments to patients in Delaware and surrounding states. Its highly trained and experienced doctors use state-of-the-art technology to perform a variety of procedures including cataract surgery, cornea & glaucoma treatments, refractive surgery, eyelid reshaping, and retina care. Led by Medical Director Dr. Jeffrey R. Boyd, M.D., Eye Care of Delaware includes one ophthalmologist and two optometrists, along with qualified support staff who coordinate patient care.

Chris Moore, CEO of Vision Innovation Partners, said, “We are delighted to welcome the team at Eye Care of Delaware to the VIP platform. VIP seeks to align with practices that want to grow and that have a great reputation for delivering superior outcomes for patients.  Dr. Boyd and his team will be a great fit as we continue to build a premier vision care platform with a mission of offering the latest technology and treatments that serve our purpose of protecting and restoring vision in patients.”

“Eye Care of Delaware is thrilled to become part of the VIP family, which shares our goal of providing advanced treatment and solutions that address our patients’ critical vision problems in a caring environment, while supporting our growth in the region. Our patients, team members and community will benefit from VIP’s additional strategic resources, business expertise, and shared vision for excellence,” said Dr. Boyd.

VIP is a portfolio company of Gryphon Investors, a leading middle market private investment firm.

# # #

About Vision Innovation Partners

Founded in 2017 and headquartered in Annapolis, MD, VIP supports the Mid-Atlantic’s premier ophthalmology practices and surgery centers through good people, expert leadership, the sharing of best practices and the backing of Gryphon Investors, a leading middle-market private equity firm. VIP’s managed practices offer a comprehensive range of services, including routine eye exams and LASIK surgery as well as treatment for cataracts, glaucoma, macular degeneration, and other ocular diseases. The Company is among the region’s leading managed services platforms for ophthalmology providers, with over 150 providers and a footprint that includes 68 locations including 12 surgery centers across Maryland, Washington D.C., Virginia, Pennsylvania and now, Delaware.

About Gryphon Investors

Gryphon Investors is a leading middle-market private investment firm focused on profitably growing and competitively advantaged companies in the Business Services, Consumer, Healthcare, Industrial Growth, Software, and Technology Solutions & Services sectors. With more than $10 billion of assets under management, Gryphon prioritizes investments in which it can form strong partnerships with founders, owners, and executives to accelerate the building of leading companies and generate enduring value through its integrated deal and operations business model. Gryphon’s highly differentiated model integrates its well-proven Operations Resources Group, which is led by full-time, Gryphon senior operating executives with general management, human capital acquisition and development, treasury, finance, and accounting expertise. Gryphon’s three core investment strategies include its Flagship, Heritage, and Junior Capital strategies, each with dedicated funds of capital. The Flagship and Heritage strategies target equity investments of $50 million to $500 million per portfolio company. The Junior Capital strategy targets investments of $10 million to $25 million in junior securities of credit facilities, arranged by leading middle-market lenders, in both Gryphon-controlled companies, as well as in other private equity-backed companies operating in Gryphon’s targeted investment sectors.

Previous Article

Categories: News

Tags:

Bridgepoint to partner with Safe Life, a global leader in AED distribution, to drive next phase of growth

Bridgepoint

Bridgepoint, one of the world’s leading quoted private asset growth investors, today announced that it has agreed to acquire a significant controlling stake in Safe Life, the global leader in the distribution of automated external defibrillators (AEDs), in a transaction that values the company at c. €500 million.

Headquartered in Stockholm, Safe Life operates across North America and Europe and is a market leader in a highly fragmented and fast-growing sector. The company equips communities and workplaces with lifesaving AEDs supported by ongoing services, including CPR training, maintenance and replacement parts such as pads and batteries to enable a fast and effective response in an emergency.

Bridgepoint will partner with Safe Life’s founders and existing institutional investors including Byggmästaren, Bonnier Capital and Swedbank Robur, all of whom are materially reinvesting alongside Bridgepoint.

Since its founding in 2019, the company has distributed over 500,000 AEDs globally and is set to deliver over €250m of sales in 2025.

Cardiac arrest remains one of the leading causes of death globally. This partnership will support Safe Life in its mission to expand access to defibrillators and help communities respond with confidence when it matters most. With Bridgepoint’s backing, the company will continue to raise awareness about the importance of AED access, ongoing maintenance, and training. It will do so through international expansion, the growth of its aftermarket and training capabilities and continued M&A, ultimately helping to save more lives in the markets it serves.

Growing public awareness and evolving health and safety regulation are driving demand, with the core AED market growing rapidly. Crucially, growth is no longer just about the supply of devices, there is increasing focus on ensuring they remain ready to use, through proper support and upkeep.

Jimmy Eriksson and Alexander Albedj, Co-Founders of Safe Life, said:

“Our mission has always been simple: to save lives by making defibrillators and training more accessible. In Bridgepoint, we’ve found a partner who not only believes in that mission but brings the expertise and scale to help us reach more communities around the world, and to support us to grow further, faster. Every second counts in an emergency, and this partnership will help ensure that time makes a difference.”

Chris Bley, Partner and Co-Head of the Nordics at Bridgepoint, added:

“We’re thrilled to be backing Safe Life’s next chapter. This is a classic Bridgepoint investment: a founder-led, mission-driven company operating in a large and growing market. Safe Life has built a standout platform, combining leadership in AED distribution with a comprehensive offer of ongoing services and maintenance, ensuring these life-saving devices are ready when they’re needed most. We see meaningful opportunities for expansion, both organically and through continued M&A, and are excited to support the team as they take the business to the next level.”

Tomas Bergström, Safe Life Chair and Byggmästaren CEO, commented:

“It has been a privilege working with Jimmy and Alexander for the past five years. They are exceptional entrepreneurs and with Bridgepoint now on board they can accelerate further. As we remain a significant shareholder I look forward to the continued journey and will support in all the ways I can.”

Safe Life operates in one of Bridgepoint’s core focus areas: Medtech products that improve patient outcomes and offer strong growth potential across multiple markets. Bridgepoint has deep experience in this space, having backed companies such as Balt, a global specialist in neurovascular devices for stroke and aneurysm treatment; and Vivacy, a European leader in regenerative and aesthetic medicine injectables.

The partnership also builds on Bridgepoint’s strong track record of supporting Swedish-founded businesses to expand internationally. Previous investments include Diaverum, a global provider of life-sustaining dialysis care operating in 23 countries, and Vitamin Well, a health and wellness drinks company with distribution across 40 markets. Both were supported by Bridgepoint’s Stockholm team and scaled significantly under its ownership through international expansion and business development.

The transaction is subject to customary closing conditions including regulatory approval and is expected to complete in Q3 2025.

Bridgepoint was advised by Jefferies (M&A Advisor), Vinge (Legal Advisor), EY (Financial, Tax & Operational Due Diligence), Strategy& (Commercial), ERM (ESG) and Marsh (Insurance).

Safe Life was advised by Baker & McKenzie (Legal Advisor).

Categories: News

Tags:

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

GIlde Healthcare
  • Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors 
  • Proceeds will support clinical development of lead program SB-007 in Stargardt disease  
  • Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other undisclosed therapeutic areas  

 

SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.

The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and the observational POLARIS study. SB-007 is the first dual adeno-associated viral (AAV) gene therapy cleared by the Food and Drug Administration (FDA) to enter clinical development for Stargardt disease. SB-007 has also received regulatory clearance for clinical development from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene that leads to progressive vision loss and blindness, with no approved treatments available. SB-007 is designed to address the underlying genetic cause of the disease by producing a functional copy of the full-length ABCA4 protein with the potential to treat all patients, regardless of their specific ABCA4 mutation. The proceeds will also be used to accelerate SpliceBio’s pipeline of AAV gene therapy programs in ophthalmology, neurology, and other undisclosed indications that utilise the company’s proprietary Protein Splicing platform.

“This financing marks a pivotal milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and continue to expand our pipeline across ophthalmology, neurology and beyond,” said Miquel Vila-Perelló, Ph.D., Chief Executive Officer and Co-Founder of SpliceBio. “The support from such high-quality investors underscores the strength of our programs and our unique Protein Splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today. We are building a company positioned to lead the next wave of genetic medicines.”

SpliceBio is redefining and expanding the scope of diseases that can be tackled with gene therapies by addressing a fundamental limitation of AAV vectors in their inability to deliver genes that exceed their limited packaging capacity of 4.7 kilobases. Many genetic disorders remain untreatable because the necessary gene is too large to fit into the AAV vectors. SpliceBio’s unique Protein Splicing platform leverages the use of a family of proprietary, engineered proteins called inteins, originally developed at Princeton University. The company’s technology enables the splitting of the gene into two (or more) transgenes that are then delivered using dual AAV vectors. Once inside the cell, the DNA of each transgene is transcribed into messenger RNA and translated into protein. SpliceBio’s engineered inteins are designed to then assemble the full-length protein that is needed to treat the disease.

About SpliceBio 
SpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. The Company’s lead program, SB-007, targets the root cause of Stargardt disease, a genetic eye disease that causes blindness in children and adults. SpliceBio’s pipeline comprises additional gene therapy programs across therapeutic areas, including ophthalmology and neurology. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein, Protein Splicing, and protein engineering research. For additional information, please visit www.splice.bio.

About SB-007 
SB-007 is an investigational Protein Splicing dual AAV gene therapy in development for the treatment of Stargardt disease. It is designed to restore expression of the native full-length ABCA4 protein in the retina. SB-007 has been granted Orphan Drug Designation from both the FDA in the US and the European Commission in Europe. In December 2024, SB-007 received FDA IND clearance, marking the first-ever clearance for a dual AAV gene therapy in Stargardt disease. Alongside initiation of the Phase 1/2 ASTRA study, with the announcement of the first patient dosed in March 2025, SpliceBio continues to advance POLARIS, a natural history study of the disease. Both studies are actively recruiting. For more information or to enquire about participation in the studies, please visit www.splice.bio/clinical.

About Gilde Healthcare 
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Nordic Capital to partner with Minerva Imaging, to support its growth journey in the radiopharmaceutical space

Nordic Capital

The investment will be made in close partnership with the founders of Minerva, marking a joint commitment to seek to accelerate the company’s growth, international expansion and further strengthening its integrated platform and service offerings, with the ambition of building a global market-leading radiopharmaceutical platform.

Minerva Imaging (“Minerva”) is a market-leading, science-driven Contract Research Organisation (“CRO”) and Contract Development and Manufacturing Organisation (“CDMO”), specialising in the development of targeted radioligand therapies — a fast-emerging and transformative field within cancer therapeutics. The partnership will support Minerva’s growth journey and ambition to build a global market-leading radiopharmaceutical platform

With deep expertise in molecular imaging and advanced oncology and cardiovascular disease models, Minerva delivers a highly differentiated, fully integrated platform that combines scientific excellence with end-to-end service capabilities. The company partners with many of the world’s leading pharmaceutical and biotechnology companies and is widely recognised for its industry-leading expertise and best-in-class capabilities. Today, Minerva employs over 150 highly skilled professionals, including a significant number of PhD-level scientists. The company has experienced rapid growth in recent years, generating revenue of more than DKK 225 million in 2024.

The global radiopharmaceuticals market is expected to be poised for significant growth over the next decade, driven by the increasing incidence of cancer and a growing demand for precision medicines. Through its partnership with Nordic Capital, Minerva is well-positioned to scale its operations and enhance its scientific capabilities, which would enable the company to provide even greater support to its customers throughout the pre-clinical and clinical development process.

“We are incredibly proud of Minerva’s progress since its founding. Our innovative solutions are making a meaningful impact for our collaborators and customers, with the ultimate goal of helping patients. We look forward to continuing this journey together with Nordic Capital, which brings extensive expertise, a strong network, and the capital needed to support our next phase. Their support enables us to work closely with our collaborators to advance the development of novel approaches that benefit patients”, said Andreas Kjaer, Chairman and Founder, Minerva.

“Our mission is to help transform translational research and drug development for patients with an unmet need. Together with Nordic Capital, we can seek to support innovation and boost our growth via organic expansion and potential selective strategic acquisitions. Partnering with Nordic Capital for our next growth phase will enable us to strengthen and extend our integrated service offerings to our valued customers and collaborators”, said Carsten H. Nielsen, CEO and Founder, Minerva.

“Minerva is a frontrunner in its field, and we are deeply impressed by the team and what they have built over the past 15 years. Its rigorous scientific approach and well-established platform positions the company strongly to capture future growth in the radiopharmaceuticals sector. As a leading healthcare investor with deep expertise across pharma, life sciences, and pharma services – and a strong track record in supporting international expansion – we are convinced Nordic Capital is uniquely positioned to support Minerva in its next phase of growth and in broadening its research-to-clinic service offering. We are excited about the opportunity for Nordic Capital to contribute to the next phase of Minerva’s journey as a partner to the founders and management”, said Jonas Agnblad, Partner and Co-Head of Nordic Capital Evolution advisory.

As a leading healthcare investor with over three decades of experience in fostering growth and international expansion, Nordic Capital is primed to support Minerva on its future growth journey. Nordic Capital will leverage its sector and in-house operational expertise together within its expert networks to facilitate continued growth and development. With a total committed capital of EUR 3.2 billion, Nordic Capital’s Evolution platform targets investments in middle-market growth companies across Northern Europe, applying Nordic Capital’s proven sector model. Minerva marks the eleventh investment made by Nordic Capital Evolution since 2021.

It has been agreed that the terms of the transaction shall not be disclosed. Completion of the transaction is expected in Q3 2025 and is subject to customary regulatory approvals and closing conditions.

Media contacts:

Nordic Capital
Katarina Janerud
Communications Manager, Nordic Capital Advisors
+46 8 440 50 50
katarina.janerud@nordiccapital.com

Minerva Imaging
Carsten H. Nielsen
CEO, Minerva Imaging
info@minervaimaging.com

About Minerva Imaging
Minerva Imaging is an integrated CRO and CDMO specialised in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services. www.minervaimaging.com

About Nordic Capital
Nordic Capital is a leading sector-specialist private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and Services & Industrial Tech. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested c. EUR 28 billion in 150 investments. Nordic Capital’s most recent funds are Nordic Capital XI with EUR 9 billion in committed capital and Nordic Capital Evolution II with EUR 2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. www.nordiccapital.com.

Categories: News

Tags:

EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray

Life Sciences

  • Series A Funding will be used to advance Mosanna’s nasal spray therapy through Phase 2 Clinical Trials
  • Biotech veteran David Weber has been appointed CEO to lead the company through clinical development
  • Obstructive sleep apnea (OSA) affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Mosanna Therapeutics (“the Company”). The clinical-stage biotech company headquartered in Basel, Switzerland, is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA) that aims to restore the body’s natural airway control. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).

“What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue” said Daniela Begolo, Ph.D., Managing Director at EQT Life Sciences, who will be joining the Board of Directors. “MOS118 is the first therapy with the potential to restore the body’s natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved.” 

OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA’s prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. 

Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body’s natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that in OSA patients, the natural airway reflex becomes less active at night, leading to a loss of airway patency and the occurrence of apnea. The new funding will support the advancement of MOS118 through Phase 2 development while also supporting the expansion of Mosanna’s pipeline. 

Mosanna also appointed veteran biotech leader David Weber, Ph.D., as President and Chief Executive Officer to guide Mosanna’s next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna’s Board of Directors. 

“Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,” said Dr. Weber. “No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options.” 

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.

 

About Mosanna Therapeutics 

Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised over $80 million from investors including EQT Life Sciences, Pivotal bioVenture Partners, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland. For more information, visit mosanna.com

Categories: News

Tags:

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

No Comments
Thomabravo

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo and Company Management to Accelerate NextGen Healthcare’s Growth

NextGen Healthcare President and COO Srinivas (Sri) Velamoor will Succeed David Sides as CEO after Planned Transition Period; Sides will Continue to Serve on Board of Directors and Remain Material Investor

CHICAGO & SAN FRANCISCO & REMOTE-FIRST COMPANY—NextGen Healthcare, Inc. (“NextGen Healthcare” or the “Company”), a leading provider of innovative, cloud-based healthcare technology solutions, today announced that funds affiliated with Madison Dearborn Partners, LLC (“MDP”), a leading private equity investment firm based in Chicago, have completed their acquisition of a significant ownership position in NextGen Healthcare. Thoma Bravo, a leading software investment firm, retains a significant ownership position in NextGen Healthcare. MDP will partner with Thoma Bravo and Company management to accelerate NextGen Healthcare’s growth.

Since acquiring NextGen Healthcare in a take-private transaction in 2023, Thoma Bravo has helped the Company modernize and enhance its capabilities, solutions, and operating structure to enhance the client experience. As partners, MDP and Thoma Bravo plan to jointly underwrite a material increase in annual R&D investment over the next three years and work with NextGen Healthcare’s leadership team to accelerate the delivery of best-in-class solutions and services to more healthcare clients.

NextGen Healthcare also announced that its Board of Directors has appointed NextGen Healthcare’s President and Chief Operating Officer Srinivas (Sri) Velamoor, as Chief Executive Officer, effective following a planned transition period. Velamoor will succeed David Sides, who will continue to serve on the Board and remain a material investor in NextGen Healthcare. Sides will work closely with Velamoor to ensure a seamless transition and will continue to support the Company’s strategic priorities throughout the transition period and beyond. Velamoor has been instrumental in driving NextGen Healthcare’s growth and innovation agenda in his current role and will assume full responsibility for leading the Company through its continued expansion and development, which is underpinned by the increased investment and ongoing support from MDP and Thoma Bravo.

The choice to elevate an established industry leader and company insider through a thoughtful and seamless transition process reflects the continued commitment of the NextGen Healthcare Board and leadership team to sustaining the Company’s growth and performance momentum and delivering market-leading services to clients.

“It has been an honor to work alongside Sri in leading NextGen Healthcare through its transformation the last several years. I am grateful to our entire NextGen Healthcare team and to our clients for their trust and partnership,” said Sides. “I am excited to support Sri as he takes the reins and leads us into this next phase of accelerating growth and impact for our clients in partnership with MDP and Thoma Bravo.”

“Our investment strategy centers around partnership with management. When we invested in NextGen Healthcare it was apparent to us how integral Sri has been to all aspects of the Company’s success. The succession announcement today is a natural progression from his previous leadership roles with the Company,” said Peter Hernandez, a Senior Vice President at Thoma Bravo. “We are excited for this next chapter with Sri at the helm, and we are pleased that David will continue to play an important role in the success of NextGen Healthcare as a member of the Board.”

“David’s vision and leadership have been instrumental in further cementing NextGen Healthcare as a category leader in the ambulatory Electronic Health Record space,” said Jason Shideler, Partner and Co-Head of Healthcare at MDP. “We are excited to partner with him and Sri to implement a succession plan for the Company and its clients as NextGen Healthcare continuously builds momentum and delivers market leading solutions and a world class service experience.”

“We are excited to welcome the MDP team as strategic partners and look forward to continuing to work with Sri and David in their new roles as they effect a seamless transition and lead this storied healthcare technology franchise into the next chapter of its growth and innovation journey,” said A.J. Rohde, Senior Partner at Thoma Bravo.

“I am humbled and privileged to be entrusted with the leadership of NextGen Healthcare’s incredible global team and to lead us through our next phase of growth and innovation,” said Velamoor. “Our colleagues, clients, and partners are unified behind our vision of achieving Better Healthcare Outcomes for All. And we are incredibly excited to partner with Thoma Bravo and MDP to unlock the many opportunities in front of us to elevate practice performance and reimagine the provider and patient experience.”

Advisors
Goodwin Procter LLP served as legal counsel to NextGen Healthcare. Morgan Stanley & Co. LLC served as lead financial advisor and J.P. Morgan Securities LLC and Evercore also served as financial advisors to NextGen Healthcare. Kirkland & Ellis, LLP served as legal counsel to MDP.

About NextGen Healthcare, Inc.
NextGen Healthcare, Inc. is a leading provider of innovative healthcare technology and data solutions. We are reimagining ambulatory healthcare with award-winning Electronic Health Record (EHR), practice management and surround solutions that enable providers to deliver whole-person health and value-based care. Our highly integrated, intelligent, and interoperable solutions increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a relentless quest to achieve better healthcare outcomes for all. Learn more at nextgen.com, and follow us on Facebook, X, LinkedIn, YouTube, and Instagram.

About Madison Dearborn Partners
Madison Dearborn Partners, LLC (“MDP”) is a leading private equity investment firm based in Chicago. Since MDP’s formation in 1992, the firm has raised aggregate capital of more than $31 billion and has completed over 160 platform investments. MDP invests across four dedicated industry verticals, including healthcare, basic industries, financial services, and technology & government. Drawing on deep industry and operational expertise, MDP works closely with management teams to drive value creation and operational improvement across its portfolio. For more information, please visit www.mdcp.com

About Thoma Bravo
Thoma Bravo is one of the largest software-focused investors in the world with a 40+ year history and approximately $184 billion in assets under management as of March 31, 2025. Through our private equity, growth equity and credit strategies, our firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Our firm has acquired or invested in approximately 535 software and technology companies representing approximately $275 billion of value (including control and non-control investments). Our investment philosophy is centered around working collaboratively with existing management teams to help drive operating results and innovation. Leveraging our deep sector knowledge and strategic and operational expertise, we execute through a partnership-driven approach supported by a set of management principles, operating metrics and business processes. We support our companies by investing in growth initiatives and strategic acquisitions designed to drive long-term value.

Read the release on Business Wire here.

Categories: News

Tags:

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

GIlde Healthcare
Aliso Viejo, CA (United States)

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term management of glaucoma and other chronic ophthalmic diseases.

Gilde Healthcare joined the Series D as a new investor alongside Sands Capital and existing investors: New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC. The funding will support the advancement of SpyGlass Pharma’s cutting-edge Drug Delivery Platform through the readout of two registrational Phase III trials, set to begin later this year.

“We appreciate the strong support from our new and existing investors, underscoring their confidence in our innovative Drug Delivery Platform,” said Patrick Mooney, CEO of SpyGlass Pharma. “We are excited to advance our platform through pivotal Phase III trials as we accelerate our commitment to addressing significant unmet needs for ophthalmic patients.

“We believe our approach represents a paradigm shift in the treatment of eye diseases, such as glaucoma, with significant advantages compared to currently commercialized therapies,” said Dr. Malik Y. Kahook, MD, Co-Founder and President of SpyGlass Pharma. “The long-term safety and efficacy demonstrated from both the first-in-human feasibility trial and the Phase II, multi-center, randomized clinical trial showing significant and sustained intraocular pressure-lowering in glaucoma patients, is compelling.”

About SpyGlass Pharma
The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues. Patients in the first-in-human study will continue to be followed over time, and the Company plans to share 24 month follow up data at the American Academy of Ophthalmology meeting later this year. SpyGlass completed enrollment in a Phase I/II study in the United States to investigate the safety and efficacy of its platform in a larger patient pool. SpyGlass looks forward to working closely with the U.S. Food and Drug Administration (FDA) to advance the program through Phase III clinical trials and ultimately to commercial approval. SpyGlass operates from its facilities in California and can be found online at www.spyglasspharma.com.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

KKR Provides $600 Million Financing to Indian Conglomerate Manipal Group

KKR

Transaction marks KKR’s latest and largest credit investment in India

MUMBAI, India–(BUSINESS WIRE)– KKR, a leading global investment firm, and Manipal Education and Medical Group (“MEMG” or “Manipal Group”), a major diversified conglomerate in India, today announced a $600-million financing arranged by KKR Capital Markets and anchored by KKR’s private credit and insurance platforms to the Manipal Group. The investment will enable the Manipal Group to accelerate its corporate expansion and growth objectives by providing flexible, structured capital matched to its long-term strategic needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250601919977/en/

The Manipal Group is a leading conglomerate in India with various institutions and major businesses across the healthcare, education, and health insurance sectors, including Manipal Health Enterprises, one of India’s top multispecialty hospitals chains in India.

KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs, promoters and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally.

Gaurav Trehan, Co-Head of KKR Asia Pacific and Head of Asia Private Equity, KKR said, “We are pleased to deepen our relationship with the Manipal Group and Dr Ranjan Pai, who have established one of India’s pre-eminent and homegrown businesses, as they continue to deliver on their long-term vision. The Manipal Group has built a strong reputation over the decades as one of India’s healthcare and education leaders, and we look forward to supporting and contributing to their continued success.”

Dr. Ranjan Pai, Chairman of Manipal Education and Medical Group, said, “We are proud to welcome KKR as a strategic partner as we continue to build on Manipal’s legacy in healthcare and education. KKR’s longstanding India focus and flexible capital approach, as well as alignment with our long-term vision, present a strong fit for us.”

Diane Raposio, Partner and Head of Asia Credit and Markets at KKR, added, “This transaction underscores the strength of our global credit platform and our ability to provide strategic, scaled capital solutions to leading businesses. India is a priority market for our credit strategy, and we look to build on this momentum to be a partner of choice to more high-quality companies like Manipal on their growth ambitions.”

KKR is making its investment from its Asia Pacific Credit strategy and insurance platform. Since 2019, KKR has committed more than $8 billion across around 60 credit investments under its Asia Pacific Credit strategy, accounting for a total transaction volume of more than $21 billion.

Additional details of the transaction are not disclosed.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Manipal Education and Medical Group (MEMG)

Founded in 1953 by Padma Shri Dr TMA Pai, MEMG has evolved into a diversified conglomerate, with a strong presence in healthcare, education and health insurance in India and globally. MEMG’s operations touch the lives of over 20 million people annually with Manipal Hospitals scaling up to become the largest tertiary network in India. MEMG’s flagship University, Manipal Academy of Higher Education has been recognized as an Institute of Eminence by the Government of India. Claypond Capital, the family office of Dr. Pai and the investing arm of MEMG has been one of the more prolific investing family offices in India in the last 18 months. Their marquee investments include Aakash, BPL Medical, BlueStone, Easy Home Finance, First Cry, Finnable, InCred Finance, NSE, Panacea Medical, PharmEasy, Purpple, Recykal, SSI Innovations and Zepto.

Media Contacts

For KKR Asia Pacific
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

For Manipal Group
Shyam Powar
+91 98804 75000
Shyam.Powar@claypondcapital.com

Source: KKR

 

Download PDF

Categories: News

Tags:

GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America

Blackstone

GRIN also announces closing of $140 million Series D financing, including a $65 million strategic equity investment from Angelini Pharma and $75 million from existing investor Blackstone Life Sciences

Collaboration combines Angelini Pharma’s global reach and focus on complex neurological disorders with GRIN’s expertise and capabilities in developing and advancing precision therapeutics for neurodevelopmental disorders

Under terms of the collaboration, GRIN is to receive $50 million upfront, and is eligible to receive up to $520 million in milestones and tiered royalties in addition to shared development costs

GRIN will continue to lead global development and retains exclusive rights for radiprodil in the United States, Canada, and Mexico

Funding from both transactions will support ongoing operations including planned global pivotal Phase 3 trial for radiprodil in the treatment of GRIN-related neurodevelopmental disorder in 3Q 2025

NEW YORK, NY, and ROME, ITALY –  May 27, 2025 – GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, and Angelini Pharma, part of the privately owned Angelini Industries, today announced a collaboration for the development and commercial rights outside of North America of GRIN Therapeutic’s investigational drug radiprodil, currently being studied in multiple rare genetic epilepsies and neurodevelopmental disorders.

GRIN Therapeutics also announced the closing of its $140 million Series D financing with investment by Angelini Pharma and Blackstone Life Sciences. Together, the two transactions highlight a significant total near-term commitment of $115 million from Angelini Pharma, which includes a $65 million strategic equity investment and a $50 million upfront payment related to the collaboration. Existing GRIN Therapeutics investor Blackstone Life Sciences contributed $75 million to the Series D financing round. Jacopo Andreose, PhD, CEO of Angelini Pharma, will join GRIN’s Board of Directors.

“We are very pleased to close this financing round and to welcome Angelini Pharma—an ideal partner whose engagement reflects the significant value we’ve built around the radiprodil program in a relatively short period,” said Bruce Leuchter, MD, President & CEO of Neurvati Neurosciences and GRIN Therapeutics. “This strategic collaboration marks an important point of validation for GRIN Therapeutics, the clinical data generated to date, and the potential of radiprodil as the first approved treatment for patients with GRIN-related neurodevelopmental disorder (GRIN-NDD)—a population with urgent unmet need. We are also deeply grateful for the continued support and commitment of Blackstone Life Sciences, whose partnership has been instrumental in advancing our efforts. With this momentum, we are well-positioned to move radiprodil into pivotal trials and take an important step toward delivering a novel therapeutic option to patients and families.”

“Our strategic collaboration with GRIN Therapeutics, including our participation in this Series D financing and in-licensing deal for radiprodil, reflects our dedication to advancing highly innovative treatments in brain health, building on our deep therapeutic expertise in neurology and psychiatry” said Jacopo Andreose, PhD, CEO of Angelini Pharma. “We see radiprodil as an opportunity to address the substantial unmet medical need of people living with GRIN-NDD and potentially other rare pediatric neurological diseases. We look forward to working closely with the team at GRIN Therapeutics to help bring this promising therapy to patients around the world.”

“Angelini Pharma is a leading international pharmaceutical company and we are thrilled to have their backing, partnership and commitment to the further growth of GRIN Therapeutics and development of radiprodil,” said Kiran Reddy, MD, Senior Managing Director, Blackstone Life Sciences. “The team’s rapid progress with radiprodil—achieving multiple regulatory designations and advancing toward a pivotal Phase 3 trial— is very promising and today’s milestone also validates the ability of Neurvati’s model to efficiently develop high-impact neuroscience therapies.”

Radiprodil is a targeted, selective, and potent negative allosteric modulator of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor. NMDA receptors are crucial for synaptic transmission, cognition and seizures. Several NDDs and epilepsy syndromes are associated with either genetic mutations or overactivation of NMDA receptors.

Radiprodil has received multiple regulatory designations, including Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with GRIN-NDD with gain-of-function (GoF) variants. Additionally, radiprodil has been granted FDA Orphan Drug designation, rare pediatric disease designation, European Medicines Agency (EMA) Priority Medicines (PRIME) designation, and a positive opinion for orphan designation from the EMA Committee for Medicinal Products for Human Use (CHMP) for the treatment of GRIN-NDD. The company remains on track to initiate a global, pivotal Phase 3 clinical trial for radiprodil in GRIN-NDD in the third quarter of 2025. Additionally, an ongoing open-label Phase 1b/2a study, known as the Astroscape trial, is evaluating radiprodil in patients with tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II.

Under the terms of the agreement, GRIN Therapeutics will continue to lead global development and retain exclusive rights for radiprodil in the United States, Canada, and Mexico. Angelini Pharma will receive exclusive rights to commercialize radiprodil in the rest of the world. GRIN Therapeutics will receive an upfront payment of $50 million, and the parties will share certain clinical development costs for radiprodil. Additionally, GRIN Therapeutics may receive up to an additional $520 million based on achieving certain development, regulatory and sales milestones.  GRIN Therapeutics is also eligible to receive tiered royalties based on global sales as well as payments from any future sublicense transactions outside of Europe.

“Our strategic collaboration with Angelini Pharma shows how global partnerships can play an important role in advancing our business strategy at Neurvati, which is purpose-built to identify, advance, and unlock the potential of promising neuroscience assets through focused, mid-to-late stage development,” said Dr. Leuchter, adding, “We are also very pleased to welcome Jacopo Andreose to our Board of Directors. His deep expertise in global drug development and commercialization will be a significant advantage for us as we progress radiprodil through Phase 3 development and prepare for potential regulatory approvals worldwide.”

About Radiprodil
Radiprodil is an investigational, potent negative allosteric modulator selectively targeting the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor, for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD).  It has been awarded Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations by the U.S. Food and Drug Administration as well as Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) and a positive opinion for orphan designation from the EMA Committee for Medicinal Products for Human Use (CHMP). The planned global Phase 3 trial for radiprodil for GRIN-NDD will aim to evaluate the impact of a targeted treatment on core aspects of the disease, including seizures, behavioral abnormalities and functional outcomes. Radiprodil is also being developed for the treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. The Astroscape trial (ClinicalTrials.gov identifier: NCT06392009) is an ongoing, open-label Phase 1b/2a clinical trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in patients with TSC or FCD type II.

About GRIN Therapeutics
GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. Late last year, GRIN Therapeutics reported promising topline data from a Phase 1b/2a clinical trial (the Honeycomb Trial, ClinicalTrials.gov NCT identifier: NCT05818943) evaluating radiprodil in GRIN-related neurodevelopmental disorder (GRIN-NDD) in patients with gain-of-function (GoF) variants, leading to the decision to advance to a global Phase 3 trial. The company has an additional ongoing clinical trial to evaluate radiprodil for the potential treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences. For more information, please visit www.grintherapeutics.com

About Neurvati Neurosciences
Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences, identifies and advances the development of high-potential drug candidates across the neuroscience landscape. Neurvati employs a collaborative model that establishes fit-for-purpose affiliate companies, aligning dedicated resources with long-term strategic capital to catalyze innovative treatment options in areas of unmet need. Neurvati’s team of experienced operators and drug developers seeks opportunities to challenge current treatment paradigms and make a difference for patients suffering from a wide range of neurological and psychiatric disorders. For more information, please visit www.neurvati.com

About Angelini Pharma
Angelini Pharma is an international pharmaceutical company, part of the privately owned multi-business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. For more information about Angelini Pharma please visit https://www.angelinipharma.com.

About Angelini Industries
Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. To learn more visit www.angeliniindustries.

About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has more than $12 billion in assets under management.

Corporate Contacts
GRIN Therapeutics
Elliott Ruiz, MBA
Senior Vice President, Finance & Operations
+1 201.674.5417
elliott.ruiz@neurvati.com

Angelini Pharma
Chiara Antoniucci
Global Head of Brand and Media Communications
+39 3477133926
Chiara.antoniucci@angelinipharma.com

Categories: News

Tags: